Skip to main content
. 2017 Jun 16;6(9):e1339853. doi: 10.1080/2162402X.2017.1339853

Figure 4.

Figure 4.

NK cell degranulation and activation requires the Fc portion of elotuzumab. A) Percentage of CD56dim NK cells that degranulated (CD107a+) in PBMCs from 7 healthy donors after exposure to whole Elo or F(ab')2 Elo at 1ug/ml with (+) or without (-) MM.1R targets. Horizontal lines are medians. Overhead bars mark statistical comparisons between indicated groups using one-sided Wilcoxon matched-pairs signed rank test, **- P < 0.01, ns – not significant. B) NK cell degranulation in PBMCs from 3 healthy donors after exposure to various forms of Elo alone (+ = native mAb, n/f = non-fucosylated Elo, mut = Elo Fc mutant, and Fab = F(ab')2 Elo; 1ug/ml each) with (+) or without (-) MM.1R or SLAMF7-deficient (KO) MM.1R targets (PBMC to target ratio 1:1). C) SLAMF7 expression on myeloma target cells using biotinylated Elo and streptavidin-APC. Isotype treated = gray shaded histogram, SLAMF7-deficient (KO) MM.1R = dashed line, and MM.1R = solid line. D) Activation of CD56dim NK cells in PBMC from 3 healthy donors upon exposure to indicated concentrations (µg/ml) of various forms of Elo overnight as a percentage CD56dim NK cells expressing CD69.